Wegovy 2 month results: what clinical evidence tells us

What the STEP 1 data actually shows at eight weeks

The STEP 1 trial enrolled 1,961 adults with a BMI of 30 or above (or 27 with a weight-related condition) and followed them for 68 weeks. The headline result (an average of around 15% body-weight reduction) belongs to the end of that timeline, not the start. At eight weeks, participants were typically on 0.5mg weekly, having moved up from the 0.25mg starter dose at week five. That is a long way from the 2.4mg maintenance dose most eventually reached.

Published weekly weight-loss trajectories from the STEP programme show that, during this early phase, the average cumulative loss sat broadly in the 3–6% range. For someone starting at 100kg, that translates to roughly 3–6kg by the end of month two, real, measurable progress, but far from the trial's eventual peak. The STEP 1 paper, available in full via the New England Journal of Medicine, is the primary source for these figures.

One reason the early numbers look modest is structural: semaglutide is titrated slowly to reduce gastrointestinal side effects. The gradualism is intentional, not a flaw. A question our prescribers hear regularly is whether slow early progress means the medicine is not working. The honest answer is that two months is simply too early to judge efficacy at the dose that actually delivers the trial's results.

Why month two results vary so much between individuals

Clinical trial averages smooth out considerable individual variation. Some people lose noticeably more in the first eight weeks; others lose less and then accelerate. Several factors shape the early response. Starting weight, calorie intake alongside treatment, activity levels, and individual gut-hormone sensitivity all play a part. The NHS semaglutide page notes that the medicine works by mimicking a hormone that signals fullness and slows how quickly the stomach empties, but the degree to which appetite shifts varies.

Dose timing matters too. People who tolerated the starter dose well and moved to 0.5mg at week five are in a different position at week eight than those who stayed longer at 0.25mg due to nausea. Neither path is wrong; both are clinically appropriate responses. If you want a longer view of how the curve tends to develop, the three-month results page covers what happens once doses have climbed further.

Sleep, stress, and medication interactions are also real variables that do not show up in a trial average. Some people notice that the appetite change they expected arrives later than they anticipated. That is common, and it does not mean the medicine has failed. Holding the expectation against the wrong timeline is one of the most consistent sources of disappointment in the first couple of months.

Side effects in the first two months: the pattern from trials

The STEP programme documented a familiar side-effect pattern that is useful to understand early on. Gastrointestinal effects (nausea, loose stools, constipation, reflux) were most common in the weeks immediately after a dose increase and tended to settle within a few days to two weeks as the body adjusted. By month two, many participants had moved through the worst of the initial nausea and were beginning to find the medicine easier to tolerate.

Practical habits help. Eating more slowly, keeping portions modest, and staying hydrated all make a difference. Keeping the pen in the fridge door and injecting on the same day each week builds the kind of routine that keeps dose timing consistent. If side effects feel unmanageable, that is a conversation for your prescriber, not something to push through silently. The option to stay at a lower dose for longer is always available, the schedule is guided by tolerance, not a fixed calendar.

For context on how results continue to develop, the six-month results page shows how cumulative loss compounds as doses stabilise. Curious about what progress typically looks like a little further along, you can read about what most people experience at the four-month mark once doses have had more time to take effect. If you are still in the early weeks and wondering whether progress is on track, how long Wegovy takes to work explains the broader timeline in plain terms. The Wegovy overview covers licensing, eligibility and how the medicine is used in the UK, and our clinical team brings that same evidence base to every consultation they review.

Putting two-month results in context before making decisions

It is worth being clear about what two-month results should and should not be used for. They are not a reliable basis for deciding whether Wegovy is working, not at dose levels that are still climbing. The STEP trials were 68 weeks long for a reason: sustained weight management requires time at an effective dose, alongside dietary and activity changes. Expecting the full trial result at eight weeks is like judging a marathon by the 5km split.

What two months of data can reasonably tell you is that the medicine is being tolerated, that doses are progressing as planned, and that the direction of travel is right. If weight is completely unchanged after eight weeks and doses have advanced appropriately, that is worth discussing with your prescriber. But small losses, or losses that feel slower than expected, are almost always consistent with a normal early trajectory.

For those interested in what the private route to treatment looks like, the Wegovy access page outlines how a prescription works through a regulated UK pharmacy, and our weight-loss treatment overview sets out the broader options. If you would like a prescriber to assess whether Wegovy is suitable for you, the right step is a clinical consultation rather than self-assessing against a trial average. Speak to our prescribers and get a same-day clinical review from a GPhC-registered professional who can look at your full picture.